Company Overview: Myomo

About the Company

Myomo
Facebook Tweeter Linkedin

Patented EMG (electromyography) control software continuously monitors and senses, but does not stimulate, the affected muscles. The user self initiates and achieves natural movement patterns by their own muscular signals that indicate intention to move. The system senses even a very weak EMG muscle signal and then processes data to a motor on the device that enables desired motion. This processing occurs so quickly that it is not apparent to the patient. Importantly, the EMG-driven device requires that users are actively engaged throughout the movement; if they stop, the device stops. No electrical stimulation or invasive procedures are employed.

By supporting the research into Myoelectric technology in 1990†, the Veterans Administration promoted and inspired development for a future myoelectric orthosis that could be of benefit to Veterans that have upper extremity impairment. Today, Myomo is assisting Veterans with MyoPro.


Investor Toolkit

Company News

  • Myomo to Present at Noble Capital Markets’ 14th Annual Investor Conference

    Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced that it will be presenting at NobleCon14 – Noble Capital Markets’ Fourteenth Annual Investor Conference at the W Hotel, Fort Lauderdale, Florida...

  • Myomo, Inc. Announces Full Exercise of Underwriter’s Over-Allotment Option in Follow-On Public Offering

    Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that Roth Capital Partners, the underwriter of Myomo’s follow-on offering, exercised in full its option to purchase 626,250 shares of common stock and accompanying warrants to...

  • Myomo, Inc. Announces Pricing of Public Offering

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO), a commercial stage medical robotics company, today announced that it has priced an underwritten public offering of 4,175,000 shares of its common stock and accompanying warrants to purchase 4,175,000 shares of...

  • Myomo Expands MyoPro® Centers of Excellence Program

    CAMBRIDGE, Mass.–(BUSINESS WIRE)– Myomo, Inc. (NYSE American: MYO) (“Myomo” or the “Company”), a commercial stage medical robotics company, today announced the addition of six new orthotics and prosthetics (O&P) locations to its Center of Excellence (CoE) program, which recognizes...

Email Subscription

Follow

Follow this blog

Get every new post delivered right to your inbox.

Email address